Released Nov 3, 2022, after the close
10-Q filed Nov 3, 2022, 34 days after period end · 0000950170-22-021840
Q3 2022 · 10-Q
Revenue$14.98M$14.98M +5.3% vs Q3 2021−19.2% vs Q2 2022
Net Income-$83.56M-$83.56M N/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.86-$0.86 N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$86,391,000N/M
Operating Cash Flowderived-$55,047,000N/M
Free Cash Flowderived-$63,723,000N/M
Margins · derived
Operating margin-576.7%−192.7 pt vs Q3 2021
Net margin-557.8%−253.3 pt vs Q3 2021
What the release said
The release
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $14.98M | $14.23M | $7.56M | $2.43M |
| Net Income | -$83.56M | -$43.31M | -$58.68M | -$26.61M |
| EPS Diluted | -$0.86 | -$0.45 | -$0.68 | -$0.40 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR